Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment
- 1 June 2008
- journal article
- case report
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (6), 2263-2265
- https://doi.org/10.1128/aac.01568-07
Abstract
We describe a case of recurring Candida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.Keywords
This publication has 14 references indexed in Scilit:
- Resistance to echinocandin-class antifungal drugsDrug Resistance Updates, 2007
- Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during TherapyAntimicrobial Agents and Chemotherapy, 2006
- Progressive Esophagitis Caused byCandida albicanswith Reduced Susceptibility to CaspofunginPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Amphotericin B and Caspofungin Resistance in Candida glabrata Isolates Recovered from a Critically Ill PatientClinical Infectious Diseases, 2006
- Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitisJournal of Antimicrobial Chemotherapy, 2006
- Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Multiechinocandin- and Multiazole-ResistantCandida parapsilosisIsolates Serially Obtained during Therapy for Prosthetic Valve EndocarditisAntimicrobial Agents and Chemotherapy, 2005
- Emergence of disseminated candidiasis caused byCandida kruseiduring treatment with caspofungin: Case report and review of literatureMedical Mycology, 2005
- Multilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedCladesJournal of Clinical Microbiology, 2003
- Caspofungin: first approved agent in a new class of antifungalsExpert Opinion on Pharmacotherapy, 2003